ADIL Adial Pharmaceuticals Inc

Price (delayed)

$2.31

Market cap

$4.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.71

Enterprise value

$367,665

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 4
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, ...

Highlights
The company's EPS has surged by 76% YoY and by 27% QoQ
Adial Pharmaceuticals's net income has increased by 13% YoY and by 2.6% from the previous quarter
ADIL's equity has soared by 75% YoY but it is down by 30% QoQ
Adial Pharmaceuticals's quick ratio has surged by 70% YoY but it has decreased by 28% QoQ

Key stats

What are the main financial stats of ADIL

ADIL stock price

How has the Adial Pharmaceuticals stock price performed over time
Intraday
-0.43%
1 week
-8.7%
1 month
44.38%
1 year
-86.17%
YTD
-58%
QTD
29.05%

Financial performance

How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.53M
Net income
-$7.77M
Gross margin
N/A
Net margin
N/A
The operating income rose by 13% year-on-year and by 3.4% since the previous quarter
Adial Pharmaceuticals's net income has increased by 13% YoY and by 2.6% from the previous quarter

Price vs fundamentals

How does ADIL's price correlate with its fundamentals

Growth

What is Adial Pharmaceuticals's growth rate over time

Valuation

What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.89
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 76% YoY and by 27% QoQ
The stock's price to book (P/B) is 75% less than its 5-year quarterly average of 3.5 and 11% less than its last 4 quarters average of 1.0
ADIL's equity has soared by 75% YoY but it is down by 30% QoQ

Efficiency

How efficient is Adial Pharmaceuticals business performance
ADIL's return on assets is up by 28% year-on-year and by 10% since the previous quarter
ADIL's ROE is up by 26% YoY and by 11% QoQ

Dividends

What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADIL.

Financial health

How did Adial Pharmaceuticals financials performed over time
Adial Pharmaceuticals's quick ratio has surged by 70% YoY but it has decreased by 28% QoQ
ADIL's current ratio has surged by 60% year-on-year but it is down by 28% since the previous quarter
Adial Pharmaceuticals's debt is 100% less than its equity
ADIL's equity has soared by 75% YoY but it is down by 30% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.